Phaos Technology (Cayman) Holdings Ltd (POAS) Financial Ratio Screen

NYSE Healthcare Singapore USD 22M
FINANCIAL SCREEN PASSED*
Automated financial screen · activity assessed separately
Phaos Technology (Cayman) Holdings Ltd (POAS) passes all available checks in 2 implemented financial-ratio model(s). Its activity assessment is still in progress; this is not a Shariah verdict. Its debt proxy is 13.7% against the model threshold of 30%. The supplied classification is Healthcare (Medical Devices); mixed activities and revenue segments remain part of the activity assessment.

Track POAS screening changes

Get an email when this stock's published screening status or underlying ratios change.

MSCI new-inclusion financial-ratio snapshot

POAS financial screening at a glance

FINANCIAL SCREEN PASSED*Financial ratios shown separately from business review — not a fatwa
Debt ratio
13.7%
Pass vs 30%
Cash ratio
6.7%
Pass vs 30%
Receivables + cash
29.4%
Pass vs 30%
Impermissible income
3.5%
Pass vs 5%

Calculation date: 2026-08-31. Financial period used: April 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.

Independent method comparison

What the available screens say

How MSCI, FTSE and S&P-style screens differ
Request this stock review
MSCI-styleFinancial criteria passedActivity is assessed separately
FTSE/Yasaar-styleFinancial criteria passedActivity is assessed separately
S&P-style provisionalNot yet availableRequired denominator or financial data is incomplete
Business activityAssessment pendingFinancial results do not determine business permissibility
Complete screening result: not yet completeA complete result requires both supported financial criteria and adequate activity evidence. This site does not issue a fatwa or official index decision.
Financial periodApril 2025Calculation date2026-08-31S&P-style historynot availableLast activity reviewnot yet reviewed

The request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.

Business activity evidence

Activity assessment in progress

The supplied classification (Medical Devices) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.

Revenue segments: Not yet checked against an SEC annual filing.

Profile description reviewed: Phaos Technology Holdings (Cayman) Limited, through its subsidiary, Phaos Technology Pte. Ltd., engages in the manufacturing and commercialization of advanced microscopy-related solutions, technologies, and products in Singapore. The company offers Optonano that enables users to view live and still images for construction of high-quality image of larger sample areas; PT-Industrial for use in material study, failure analysis, simple measuring, quality control, inspection, and manufacturing; and PT-Metrology, which provides dimensional measurements with a single key operation. It also provides PT-Biology to create specialized images needed in the biomedical sector; PT-Stereo, a stereo microscope designed to provide clear magnified stereoscopic images that amplify solid or thick samples; and PT-Zoom that offers three-dimensional magnified view of samples to enhance visualization. In addition, the company offers software. The company serves manufacturing companies; biomedical service providers; and research and development institutions. The company was founded in 2017 and is based in Singapore.

Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings

A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.

Published-ratio reproductions (not certifications)

The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.

Based on financial data from April 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
MSCI 13.7%
/ 30%
6.7%
/ 30%
29.4%
/ 30%
3.48%
/ 5%
FINANCIAL SCREEN PASSED*
FTSE 13.7%
/ 33%
6.7%
/ 33%
29.4%
/ 50%
3.48%
/ 5%
FINANCIAL SCREEN PASSED*

Financial Highlights

EPS
$-0.30
P/B Ratio
-27.1
EV/EBITDA
-11.4
EV: $44M
Revenue
$167,707
Growth: -93.1%
Current Ratio
0.4

Profitability

Gross Margin 22.1%
Operating Margin -1897.8%
Net Margin 0.0%
Return on Equity (ROE) -1073.1%
Return on Assets (ROA) -71.2%

Cash Flow & Balance Sheet

Operating Cash Flow-$4M
Free Cash Flow-$4M
Total Debt$265,824
Current Ratio0.4
Total Assets$2M

Price & Trading

Last Close$1.55
50-Day MA$2.69
200-Day MA$3.14
Avg Volume1.2M
52-Week Range
$0.53
$7.39

Financial data provenance and verification

The displayed fields were imported from yfinance on 2026-03-29 for the financial period April 2025. This is a secondary data feed and can differ from amended or newly filed statements.

Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.

About Phaos Technology (Cayman) Holdings Ltd (POAS)

CEO
Mr. Hong Loon Gan
Employees
25
Sector
Healthcare
Industry
Medical Devices
Country
Singapore
Exchange
NYSE
Market Cap (listing currency)
USD 22M
Currency
USD

Phaos Technology Holdings (Cayman) Limited, through its subsidiary, Phaos Technology Pte. Ltd., engages in the manufacturing and commercialization of advanced microscopy-related solutions, technologies, and products in Singapore. The company offers Optonano that enables users to view live and still images for construction of high-quality image of larger sample areas; PT-Industrial for use in material study, failure analysis, simple measuring, quality control, inspection, and manufacturing; and PT-Metrology, which provides dimensional measurements with a single key operation. It also provides PT-Biology to create specialized images needed in the biomedical sector; PT-Stereo, a stereo microscope designed to provide clear magnified stereoscopic images that amplify solid or thick samples; and PT-Zoom that offers three-dimensional magnified view of samples to enhance visualization. In addition, the company offers software. The company serves manufacturing companies; biomedical service providers; and research and development institutions. The company was founded in 2017 and is based in Singapore.

Popular halal stock checks

Explore other frequently viewed automated stock screens and compare the available financial ratios.

Frequently Asked Questions

Is Phaos Technology (Cayman) Holdings Ltd (POAS) halal to invest in?

The current automated result is Financial screen passed; activity assessment pending. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.

What is Phaos Technology (Cayman) Holdings Ltd's debt ratio?

Phaos Technology (Cayman) Holdings Ltd's debt ratio is 13.7% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.

What are Phaos Technology (Cayman) Holdings Ltd's key financial metrics?

Phaos Technology (Cayman) Holdings Ltd has a market capitalization of USD 22M in its listing currency, and revenue of $167,707. Return on equity stands at -1073.1%.

How often is the screening data updated?

Calculation date: 2026-08-31. Financial period: April 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.